Prevalence of aPL in SLE
| aPL | SLE/APS (n = 56) (%) | SLE/thrombosis (n = 56) (%) | SLE only (n = 56) (%) |
|---|---|---|---|
| aCL, anticardiolipin antibodies; LA, lupus anticoagulant; anti-β2GPI, antibodies to β2-glycoprotein I; aPT, antibodies to solid phase prothrombin; aPS-PT, antibodies to phosphatidylserine-prothrombin complex. By inclusion criteria no patients from the SLE/thrombosis group had aCL or LA. | |||
| aCL | 47 (84) | 0 (0) | 15 (27) |
| IgG | 43 | 0 | 14 |
| IgM | 23 | 0 | 1 |
| LA | 25 (45) | 0 (0) | 8 (14) |
| Anti-β2GPI | 33 (59) | 0 (0) | 0 (0) |
| IgG | 27 | 0 | 0 |
| IgM | 10 | 0 | 0 |
| aPT | 30 (54) | 3 (5) | 9 (16) |
| IgG | 28 | 2 | 8 |
| IgM | 3 | 1 | 1 |
| aPS-PT | 35 (63) | 1 (2) | 6 (11) |
| IgG | 26 | 0 | 5 |
| IgM | 22 | 1 | 1 |